Limiting the saturated fatty acid (SAFA) consumption forms the basis of dietary fat recommendations for heart health, despite several meta-analyses demonstrating no link between dietary SAFA and the risk of cardiovascular disease (CVD). Three experts on dietary fat and health discussed the evidence of reducing SAFA intake at a symposium of the Federation of European Nutrition Societies in Berlin, Germany, October 23, 2015. Ronald P. Mensink, Maastricht University, the Netherlands, discussed the evidence linking dietary fatty acids and CVD risk. He emphasized the importance of the replacement nutrient(s) when SAFA intake is reduced. Julie Lovegrove, University of Reading, UK, addressed the question of whether higher intakes of unsaturated fatty acids are beneficial. She discussed the replacement of SAFA by polyunsaturated fatty acids (PUFA) and monounsaturated fatty acids (MUFA), noting the reduction in CVD risk with PUFA replacement and in CVD risk markers with MUFA replacement of SAFA. Ursula Schwab, University of Eastern Finland, Kuopio, Finland, discussed the importance of dietary patterns in achieving reduced risk of CVD, observing that several dietary patterns following the principles of a health-promoting diet and adapted to local customs, food preferences and seasonality are effective in reducing the risk of CVD, type 2 diabetes and other chronic diseases. This paper summarizes the symposium presentations.

Restricting the consumption of saturated fatty acids (SAFA) to reduce the risk of cardiovascular disease (CVD) forms the basis of recent dietary fat recommendations [1,2], in spite of the disagreement about the link between dietary SAFA and CVD [3,4,5,6]. Several systematic reviews, meta-analyses [7,8] and prospective cohort studies [9] have questioned the link between SAFA and CVD risk. Recent systematic reviews, however, highlight the importance of partial replacement of SAFA by polyunsaturated fatty acids (PUFA) in decreasing the risk of CVD [1,10,11]. At the Federation of European Nutrition Societies meeting in Berlin, Germany, October 20-23, 2015 three experts on dietary fat and health discussed several aspects of current recommendations for fatty acid consumption to reduce the CVD risk. The symposium was hosted by the International Expert Movement to Improve Dietary Fat Quality [12], an initiative of the International Union of Nutritional Sciences, funded by an unrestricted education grant from Unilever NV. This paper summarizes the presentations of the symposium.

Media attention to recent studies questioning the link between the intake of SAFA and the risk of CVD has increased the confusion among consumers about consuming SAFA-rich foods [13,14]. Addressing the question of whether SAFA intakes should be reduced, Ronald P. Mensink, Maastricht University, the Netherlands, explained that the formulation of dietary recommendations mainly relies on risk biomarkers, which are causally related to CVD. Although studies examining relationships between SAFA intake and risk of coronary heart disease (CHD) are conflicting, SAFA increases low-density lipoprotein-cholesterol (LDL-C) levels compared with cis-unsaturated fatty acids. Increased LDL-C is causally related to an increased CHD risk. Hence, dietary guidelines recommend limiting SAFA intake. The 3-way relationship among SAFA, LDL-C and CHD is the cause of consumer confusion.

Questions about the link between dietary SAFA and CVD arose from the work of Siri-Tarino et al. [9] whose meta-analysis of 21 prospective cohort studies concluded that the evidence did not support an association between SAFA consumption per se and an increased risk of CVD or CHD. In another systematic review and meta-analysis of 12 prospective cohort studies, de Souza et al. [7] found neither significant association between SAFA consumption and all-cause CVD and CHD mortality nor risk of ischemic stroke or type 2 diabetes. Mensink pointed out that the key question is the effect of nutrients that replace SAFA. Thus, Jakobsen et al. [15] reported that replacement of 5% energy (En) from SAFA with PUFA was associated with a significantly reduced risk of coronary events and death (hazard ratio, HR 0.87, 95% CI 0.77-0.97; and HR 0.74, 95% CI 0.61-0.89, respectively), whereas replacement with carbohydrates was associated with a modestly higher risk of coronary events (HR 1.07, 95% CI 1.01-1.14). Evidence pooled from 2 large prospective cohort studies suggested that isocaloric replacement of 5% SAFA with PUFA or monounsaturated fatty acids (MUFA) was associated with a significant 25 or 15% reduction in CHD risk, respectively, between the highest and lowest quintiles of consumption [16]. Others have also reported that PUFA intake is associated with a lower risk of CHD when it replaces SAFA, trans fats or carbohydrates [17,18].

The main link between dietary fatty acids and CHD risk is observed from their effects on plasma or serum LDL-C levels. A fatty acid is considered hypercholesterolemic when an isoenergetic exchange of carbohydrates in the diet for the fatty acid causes an increase in the serum total cholesterol (TC) concentrations. Carbohydrates have arbitrarily been called ‘neutral'. Replacement of trans fatty acids or SAFA with PUFA leads to a significant decrease in LDL-C concentrations, with the substitution of trans-MUFA by PUFA being the most favorable.

Subsequently, Mensink questioned the best lipid biomarker or combination of lipid biomarkers to predict the risk of CHD: LDL-C, apolipoprotein B, apolipoprotein CIII, small dense LDL, high-density lipoprotein cholesterol (HDL-C), apolipoprotein A1, triacylglycerols, TC:HDL-C, postprandial metabolism, or Lp(a)? When fat is replaced by carbohydrate, one result is an increase in the prevalence of small dense LDLs, which are associated with higher CVD risk [19,20]. Increasing carbohydrate at the expense of SAFA may not improve the serum lipoprotein profile as HDL-C may be reduced and triacylglycerol increased [6]. Further, the carbohydrate type may affect the lipid response, with refined starches and sugars being associated with a comparable risk of CHD as SAFA, but those from whole grains associated with a significantly lower CHD risk [16,21].

Consumption of SAFA may affect other atherogenic pathways unrelated to lipoproteins. Examples include systemic inflammation, blood pressure, endothelial function, hemostatic function, insulin resistance, postprandial metabolism and weight gain. However, the effects of dietary SAFA on these parameters yielded mixed results.

Various SAFA behave differently, metabolically speaking, which raises the question of whether to discriminate among them for CVD risk. Although food fats contain mixtures of SAFA, the predominant ones in Western diets are palmitic (C16:0) and stearic (C18:0) acids. Dairy products are relatively rich in short- and medium-chain SAFA (C4:0-C10:0), while coconut and palm kernel oil each have relatively large amounts of lauric (C12:0) and myristic (C14:0) acids. The potency of individual longer-chain SAFA (≥C12) in raising LDL-C levels compared to carbohydrate diminishes from lauric acid with increasing chain length up to stearic acid, which generally has a neutral effect on lipid and lipoprotein levels [6].

Interestingly, the effects of various SAFA on markers of inflammation may differ from the pattern observed on plasma lipids. For example, when carbohydrate was replaced by 8% stearic acid in controlled diets consumed by healthy men, plasma fibrinogen and interleukin-6 levels were significantly increased, while the C-reactive protein did not increase significantly [22]. Although others have reported contrasting results with dietary stearic acid compared with unsaturated FA and trans MUFA [23], these studies emphasize that knowledge on the effects of individual SAFA on CHD risk markers other than serum lipids is limited.

The contribution of SAFA-related food matrix to the risk of CVD and its associated biomarkers is sometimes overlooked. A recent systematic review and meta-analysis of the effect of cheese consumption on blood lipids, for example, concluded that the consumption of hard cheese lowers LDL-C and HDL-C when compared to butter, but both had comparable effects on fasting triacylglycerol concentrations [24]. Others have also reported differences in CVD risk or plasma lipid levels depending on the food source of SAFA [25,26,27].

In brief, Mensink noted that prospective cohort studies and randomized controlled trials can be complementary or contradictory [28], as illustrated by studies on antioxidants [29], folic acid [30] and possibly SAFA [31]. He emphasized the importance of discussing the replacement nutrient(s) when SAFA intake is reduced, and observed that a food pattern or food is more than a single nutrient. Although individual SAFA are metabolized differently, whether they affect the health differently is uncertain. Resolving current issues will require studies with integrated end points or, preferably, hard end points.

Recent reports on the global risks for disease mortality and disability-adjusted life years (DALYs), that is, the years lost due to premature mortality and disability, identified diet as the predominant contributor to mortality and disability from predominantly CVD, but also diabetes and neoplasms [32]. Expressed in numbers, modifiable dietary risks accounted for 11.3 million deaths and 241.1 million DALYs worldwide in 2013. These data suggest opportunities for effective dietary prevention policies. The question of whether higher intake of unsaturated fats is beneficial to these dietary risks was addressed by Julie Lovegrove, University of Reading, UK.

There is consistent evidence that partial replacement of dietary SAFA with PUFA significantly reduces the risk of CHD events and mortality [10,11,16,18], although inconsistent or contradictory data have been reported in some secondary prevention trials [33,34]. In contrast, too few data exist to ascertain the effect of MUFA substitution on CVD mortality [11,35]. Furthermore, dietary MUFA are derived from both plant (such as olive and rapeseed oils, nuts and seeds) and animal sources (including meat and poultry). The food source may have an impact on the association between MUFA intake and disease incidence or mortality. A recent meta-analysis of 32 cohort studies comparing the top vs. the bottom third intakes of total MUFA reported significant risk reductions ranging from 9 to 17% for all-cause and cardiovascular mortality, cardiovascular events and stroke [36]. However, in sub-group analysis of MUFA of mixed origin, only higher intakes of olive oil were associated with a reduced risk of all-cause mortality, cardiovascular events and stroke.

There are 2 distinct families of PUFA, namely, omega-6 PUFA found in vegetables and vegetable oils and omega-3 PUFA, which include alpha-linolenic acid (ALA) found only in plants and eicosapentaenoic and docosahexaenoic acids (EPA and DHA), respectively, found mainly in fish and shellfish. Evidence suggests that higher dietary ALA and EPA/DHA consumption is associated with significantly reduced risk of CVD and CHD mortalities [37,38,39], although inconsistent and contradictory data have been reported [34,40]. The proposed mechanisms of action of EPA/DHA are varied and include anti-arrhythmic, anti-thrombotic and triacylglycerol-lowering effects, which may be observed within weeks [41,42,43], while changes in heart rate and blood pressure may take months [44,45 to be visible].

In a study on the relationship between circulating levels of linoleic acid (LA), the major n-6 PUFA in food and plasma, and risk of total and cause-specific mortality, LA was associated with a 13% lower risk of total mortality and a 22% lower risk of CVD mortality, comparing the top and bottom quintiles [46]. The investigators also reported a 49% lower risk of non-arrhythmic CHD mortality across quintiles of LA, but no significant association with arrhythmic CHD mortality. With stratification of the participants on both LA and n-3 PUFA, those with the highest circulating levels of both types of fatty acids had a 54% lower risk of CVD death compared to those with the lowest levels. These data support the benefits of PUFA and CVD risk reduction.

There is scientific consensus that high intakes of industrially produced trans unsaturated fatty acids, mainly trans-elaidic acid (18:1t9), are detrimental to heart health [7,47]. It is less clear whether the trans fatty acids produced in ruminants via the bacterial metabolism of unsaturated fatty acids, as found in dairy products and meats, are also harmful. The main trans fatty acid found in ruminant fats is vaccenic acid (18:1t11), although lesser amounts of trans palmitoleic (C16:1t9) are also present. The latter is increasingly recognized as a biomarker of dairy intake, as humans are only able to endogenously synthesize this from vaccenic acid, which originates in dairy fats [48]. Systematic reviews and studies have reported that ruminant trans fatty acids are not associated with CHD [7,49] or CVD risk markers [50], but other published reports suggested that both ruminant and industrial trans produced from partially hydrogenated oils are associated with an increased CVD risk [51,52,53].

Recent investigations on trans-palmitoleic acid reported relations between circulating levels and higher LDL-C, but significantly lower triacylglycerols, incident diabetes and atherogenic dyslipidemia [54,55]. Of interest are findings from a German cohort of patients scheduled for coronary angiography in which total trans and trans-palmitoleic acids in erythrocyte membranes were inversely associated with the risk of cardiovascular mortality and sudden cardiac death [56]. However, it is of particular interest that the concentrations of trans fatty acids in this cohort were low compared with values in US populations for the same time period (0.96 ± 0.3 vs. 2.68 ± 0.8%). Further clarity is required to establish the specific impact of ruminant trans on disease risk.

CVD risk factors include both modifiable and non-modifiable components, with diet and lifestyle contributing to modifiable factors, such as LDL-C, blood pressure, elevated triacylglycerols, vascular function, inflammation, obesity and diabetes [57]. Diet modification focused on improving blood lipids by the partial replacement of SAFA intakes with unsaturated fatty acids. An early review of metabolic ward studies demonstrated that isocaloric replacement of 5% of calories from SAFA with PUFA or MUFA reduced the total blood cholesterol by 0.39 and 0.24 mmol/l, respectively, with the main reduction occurring in LDL-C [58]. There is consistent evidence from randomized controlled trials that replacement of SAFA with unsaturated fatty acid reduces lipid risk biomarkers [10].

Jebb et al. [59] reported that replacement of SAFA with MUFA or carbohydrate resulted in a significantly lower TC and LDL-C, but only MUFA replacement was associated with a significantly lower TC:HDL-C ratio, a clinically recognized biomarker of CVD [59,60]. Replacing 9.5%En from SAFA with MUFA or n-6 PUFA resulted in a significantly lower TC and LDL-C and TC:HDL-C ratio after 4 months [61]. Several studies concluded that partial replacement of dietary SAFA with PUFA results in the greatest reduction in the risk of CVD, events and risk factors [11,16,62]. In their review of substituting increasing levels of %En from carbohydrates with different fatty acids, Micha and Mozaffarian [62] reported that MUFA and PUFA reduced the ratio of TC:HDL-C to the greatest extent, trans fatty acids increased the ratio significantly, but SAFA had no significant effect.

Lovegrove discussed factors other than blood lipids that contribute to the risk of CVD mortality, particularly high blood pressure. In a parallel-group study of diets rich in SAFA, MUFA or PUFA, consumed for 16 weeks by men and women with moderate CVD risk, consumption of MUFA-rich diet attenuated a significant increase in night systolic blood pressure (SBP) observed with SAFA [61]. In a meta-analysis of 12 randomized controlled trials on diets high (>12%En) or low (≤12%En) in MUFA and risk factors for obesity and CVD, Schwingshackl et al. [63] reported significant reductions in systolic and diastolic blood pressures with diets containing >12%En from MUFA and significantly lower fat mass.

Arterial stiffness, an independent predictor of CVD, is affected by dietary fatty acid consumption [64]. In a study of men aged 45-59 years, who were followed for a mean of 17.8 years, higher consumption of PUFA at baseline was associated with significantly lower systolic and diastolic blood pressures and pulse wave velocity, a measure of arterial stiffness, compared with men having a higher intake of SAFA [65]. Additional confirmation is, however, required.

Dietary fat may also affect insulin sensitivity in healthy adults. Vessby et al. [66] reported that with diets having >37%En from fat, the quality of fat did not affect insulin sensitivity; however, in diets with <37%En from fat, the substitution of MUFA for SAFA significantly improved insulin sensitivity in healthy volunteers. However, in the RISCK study, volunteers with symptoms of metabolic syndrome who consumed diets in which SAFA were replaced with MUFA or carbohydrates with high or low glycemic index showed no improvement in insulin sensitivity with any of the replacement diets [59]. A similar lack of effect of SAFA substitution with MUFA or carbohydrate on insulin sensitivity was observed in LIPGENE, another large randomized controlled trial performed in a pan-European population with metabolic syndrome [67]. While others also found no evidence for the effect of dietary SAFA on insulin resistance or type 2 diabetes [68], a recent review of MUFA vs. SAFA on insulin sensitivity concluded that the strength of the evidence favoring MUFA over SAFA was probable because of the small number of participants, although neither the RISCK nor LIPGENE data were included in this analysis [10].

Liver and visceral fat are contributing factors to cardiometabolic risk and insulin resistance that can be modified through diet. Excess energy intake leads to fat accumulation in liver and pancreas, which results in insulin resistance, beta-cell dysfunction, hyperglycemia, dyslipidemia and vascular dysfunction [69]. Compared with the consumption of PUFA, high-SAFA intakes, mainly from palm oil, increased the accumulation of liver fat and visceral adipose tissue in young, normal-weight, overfed adults, while high PUFA intakes resulted in a nearly 3-fold increase in lean tissue compared with SAFA [70]. Similar findings for liver fat were reported in abdominally obese participants who consumed either SAFA-rich (mainly butter) or n-6 PUFA-rich diets for 10 weeks [71]. In addition, those who consumed the n-6 PUFA-rich diet showed a modest improvement in serum lipids and insulin levels without signs of inflammation or oxidative stress.

Lovegrove concluded that the replacement of SAFA by PUFA is associated with a reduction in CVD (risk and mortality); replacement by PUFA or MUFA is associated with reduced lipid markers of cardiovascular risk; replacement by MUFA is associated with a reduction in other risk markers, such as SBP; and minimization of trans fatty acid consumption benefits cardiovascular health. For dietary policy, it is important to use the totality of evidence and multiple validated risk factors for mortality, and to translate nutrient intakes to foods and diets.

Recent dietary guidelines have shifted their focus from single nutrients to foods and dietary patterns, partly to make recommendations more relevant to consumers, and partly from increased awareness of nutrient and food matrix interactions. Overall, healthy dietary patterns have been associated with a lower risk of most chronic diseases, although different approaches have been used to evaluate various food patterns [72]. Discussing food-based dietary guidelines, Ursula Schwab, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland, explained that nutrient-based guidelines have been difficult to interpret by various users - the general population, food services, industry - and that people eat foods, not nutrients in isolation. It is also thought that it will be easier for people to adhere to a healthy food pattern rather than nutrient-based recommendations as indicated by recent studies [73].

Food patterns have been studied in whole diet trials, such as those involving the Mediterranean [74,75], Dietary Approaches to Stop Hypertension (DASH) [76], and healthy Nordic diets [77], and epidemiological studies [72] and systematic reviews [74,75]. Whole diet trials have yielded similar and consistent conclusions on weight loss, reduction in CVD risk factors and improved longevity [78]. Epidemiological studies have shown that dietary patterns rich in vegetables, fruits, nuts, whole grain cereals, fish, low-fat dairy products and vegetable oils, but low in refined cereals and sugar-rich products, red and processed meats are associated with a lower risk of most chronic diseases [57,79]. Systematic reviews have also found consistent benefits for similar diet patterns and lower risks of incident or fatal CHD, breast cancer, all-cause mortality, CVD, cancer and neurodegenerative diseases [31,74,80]. Several studies have reported inverse association between various healthful dietary patterns or scores and risk of type 2 diabetes [81,82,83].

The DASH diet, described in 1997 [84], was the first to combine several dietary modifications - increased fruits and vegetables, fat-free and low-fat dairy products, whole grain foods, poultry, fish, nuts and unsaturated fat - with reductions in dietary saturated fat, red meat, sweets, sugar-sweetened beverages and salt. This diet resulted in significant reductions in systolic and diastolic blood pressures in hypertensive and normotensive participants over 8 weeks compared with those consuming a controlled diet or a diet rich in fruits and vegetables only.

In a review of 20 randomized controlled trials, Shirani et al. [85] reported that a 16-week DASH diet significantly reduced the fasting insulin concentration in patients with metabolic syndrome or dyslipidemia. The diet did not affect fasting glucose concentrations.

Most studies of the Mediterranean diet in the context of type 2 diabetes and CVD have shown favorable effects on glycemic control and CVD risks, although there is some controversy about obesity [86,87]. A recent 4-year prospective cohort study examined the relationship between the Mediterranean diet and mortality in individuals with type 2 diabetes. The traditional Mediterranean diet was associated with a reduced risk of total and CVD mortality, independent of disease severity [88]. Principal factor analysis suggested that the main contributors to the effect of diet were moderate alcohol, high intake of cereals, fruits and nuts and lower consumption of dairy and meat products. In an intervention study of the primary prevention of CVD in 418 high-risk individuals (PREDIMED), 2 variations of the Mediterranean diet, supplementation with either virgin olive oil or nuts, were compared with a controlled diet of about similar fat content (41%En) [89]. After 4 years, the incidence of type 2 diabetes was significantly lower in the 2 Mediterranean diet groups, 10.1 and 11.0%, respectively compared with 17.9% in the control group (40%En from fat). When the 2 diet groups were pooled, the risk of type 2 diabetes was reduced by 52% compared with the control group. These changes occurred with no change in body weight or physical activity. In the full cohort of 7,447 participants, the HRs for incident type 2 diabetes were 0.60 (95% CI 0.43-0.85) and 0.82 (95% CI 0.61-1.10) for olive oil and nut-supplemented diets, respectively [90]. The HRs for CVD events, including myocardial infarction, stroke or CVD death, were 0.70 (95% CI 0.53-0.91) and 0.70 (95% CI 0.53-0.94) for the 2 diet groups compared with the control group. Several classical and emerging risk factors for CVD were also favorably affected.

Other healthy diet patterns modeled on the Mediterranean diet, such as the healthy Nordic diet [91], have been developed to include local customs, food preferences and seasonality. Compared with the Mediterranean diet, the healthy Nordic diet includes rapeseed (canola) oil in place of olive oil; seasonal fruits, berries, root vegetables, pulses and nuts; vegetables with rapeseed oil salad dressings; consumption of fatty and other fish, game, whole grains and low-fat/non-fat milk products; and avoidance of butter, fatty dairy products, salted foods and red meat. In a randomized, controlled trial of 88 hypercholesterolemic patients, those consuming the healthy Nordic diet for 18-24 weeks experienced significant reductions in plasma TC, LDL-C, HDL-C, LDL-C:HDL-C ratio and apolipoprotein B compared with those on the control diet [92]. In a different study, the healthy Nordic diet was associated with a significant reduction in obesity-related markers of inflammation, for example, hs-C-reactive protein [93]. The healthy Nordic diet was also associated with the down-regulation of genes involved in subcutaneous adipose tissue inflammation in obese individuals with the metabolic syndrome, independent of body weight change [94].

The principles of the healthy Nordic diet were incorporated into a successful lifestyle intervention program to prevent type 2 diabetes in participants with impaired glucose tolerance [95]. Reduced consumption of total fat and SAFA with increased intake of dietary fiber and the addition of more than 4 h/week of physical activity resulted in a significant reduction in the risk of developing type 2 diabetes in a median follow-up of 9 years (HR 0.61, 95% CI 0.48-0.79) compared to the control group [95]. Six key Nordic foods formed the basis of the healthy Nordic food index, which was associated with an 18% lower total mortality between the highest and lowest diet scores over 21 years in Swedish women [96]. However, the diet was not associated with CVD risk in the same cohort [97]. In a Danish cohort, greater adherence to the healthy Nordic index was associated with a 25% lower risk of type 2 diabetes over 15 years in women and a 38% lower risk in men [98].

Schwab concluded that the beneficial effects of health-promoting diets have been shown to reduce the risk of CVD, type 2 diabetes and other chronic diseases in several studies using different methods [57,72,99]. Taking into account the local food culture also improves dietary adherence.

In summary, symposium participants agreed that dietary guidelines should continue to recommend limiting dietary SAFA consumption, but at the same time emphasize the importance of replacing SAFA with PUFA to reduce CVD risk. Replacement of trans-fatty acids with PUFA has the most favorable effect on reducing LDL-C and therefore the CVD risk. Partial replacement of SAFA with MUFA may reduce some risk markers for CVD, but data are inconclusive about the effect of MUFA on the risk of CVD mortality. Participants agreed that dietary recommendations should shift their focus away from single nutrients toward more healthy foods, such as whole grains, and dietary patterns, such as the Mediterranean, DASH and healthy Nordic diets, which promote health and reduce the risk of CVD, type 2 diabetes and other chronic diseases.

In the general discussion, one audience member asked the presenters whether reducing the dairy fat intake was important if an individual was not obese. Lovegrove responded that it is recommended that dietary SAFA should be reduced to <10%En irrespective of body weight. However, despite the SAFA content, milk and dairy food consumption has been associated with lower cardiometabolic risk, possibly due to other dairy constituents, such as calcium and bioactive peptides [100,101]. Another participant wondered whether an energy-reduced diet for overweight diabetic individuals should have more or less fat or carbohydrate. Schwab replied that the aim with such patients was not just weight loss, but also the overall improvement of the diet. The evidence suggests that diabetic patients can lose weight and improve their glycemic control with a variety of macronutrient interventions that include reduced energy intake, regular physical activity, education and support [102].

Selected material from this report was originally presented at the Federation of European Nutrition Societies meeting in Berlin, Germany, October 23, 2015. Unilever, the Netherlands, provided financial assistance for this publication and travel support for J.A.N., R.P.M., J.A.L. and U.S.

The authors declare no conflicts of interest.

1.
Wolfram G, Bechthold A, Boeing H, Ellinger S, et al: Evidence-based guideline of the German nutrition society: fat intake and prevention of selected nutrition-related diseases. Ann Nutr Metab 2015;67:141-204.
2.
US Department of Health and Human Services and US Department of Agriculture: 2015-2020 Dietary Guidelines for Americans, ed 8. Washington, US Department of Health and Human Services and US Department of Agriculture, 2015.
3.
Williams CM, Salter A: Saturated fatty acids and coronary heart disease risk: the debate goes on. Curr Opin Clin Nutr Metab Care 2016;19:97-102.
4.
Dawczynski C, Kleber ME, März W, Jahreis G, et al: Saturated fatty acids are not off the hook. Nutr Metab Cardiovasc Dis 2015;25:1071-1078.
5.
DiNicolantonio JJ, Lucan SC, O'Keefe JH: The evidence for saturated fat and for sugar related to coronary heart disease. Prog Cardiovasc Dis 2016;58:464-472.
6.
Siri-Tarino PW, Chiu S, Bergeron N, Krauss RM: Saturated fats versus polyunsaturated fats versus carbohydrates for cardiovascular disease prevention and treatment. Annu Rev Nutr 2015;35:517-543.
7.
de Souza RJ, Mente A, Maroleanu A, Cozma AI, et al: Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. BMJ 2015;351:h3978.
8.
Siri-Tarino PW, Sun Q, Hu FB, Krauss RM: Saturated fat, carbohydrate, and cardiovascular disease. Am J Clin Nutr 2010;91:502-509.
9.
Siri-Tarino PW, Sun Q, Hu FB, Krauss RM: Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. Am J Clin Nutr 2010;91:535-546.
10.
Schwab U, Lauritzen L, Tholstrup T, Haldorssoni T, et al: Effect of the amount and type of dietary fat on cardiometabolic risk factors and risk of developing type 2 diabetes, cardiovascular diseases, and cancer: a systematic review. Food Nutr Res 2014;58:25145.
11.
Hooper L, Martin N, Abdelhamid A, Davey Smith G: Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev 2015;6:CD011737.
12.
International Expert Movement to Improve Dietary Fat Quality. Vlaardingen, Unilever/International Union of Nutritional Science, 2016.
13.
Gallagher J: Diet debate: is butter back and is sat fat good? BBC News Website, 2016.
14.
Shilhavy B: Time Magazine: We Were Wrong About Saturated Fats: Health Impact News, 2016.
15.
Jakobsen MU, O'Reilly EJ, Heitmann BL, Pereira MA, et al: Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies. Am J Clin Nutr 2009;89:1425-1432.
16.
Li Y, Hruby A, Bernstein AM, Ley SH, et al: Saturated fats compared with unsaturated fats and sources of carbohydrates in relation to risk of coronary heart disease: a prospective cohort study. J Am Coll Cardiol 2015;66:1538-1548.
17.
Virtanen JK, Mursu J, Tuomainen TP, Voutilainen S: Dietary fatty acids and risk of coronary heart disease in men: the Kuopio ischemic heart disease risk factor study. Arterioscler Thromb Vasc Biol 2014;34:2679-2687.
18.
Mozaffarian D, Micha R, Wallace S: Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med 2010;7:e1000252.
19.
Krauss RM, Blanche PJ, Rawlings RS, Fernstrom HS, et al: Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia. Am J Clin Nutr 2006;83:1025-1031; quiz 1205.
20.
Mora S, Szklo M, Otvos JD, Greenland P, et al: LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis 2007;192:211-217.
21.
Jakobsen MU, Dethlefsen C, Joensen AM, Stegger J, et al: Intake of carbohydrates compared with intake of saturated fatty acids and risk of myocardial infarction: importance of the glycemic index. Am J Clin Nutr 2010;91:1764-1768.
22.
Baer DJ, Judd JT, Clevidence BA, Tracy RP: Dietary fatty acids affect plasma markers of inflammation in healthy men fed controlled diets: a randomized crossover study. Am J Clin Nutr 2004;79:969-973.
23.
Tholstrup T: Influence of stearic acid on hemostatic risk factors in humans. Lipids 2005;40:1229-1235.
24.
de Goede J, Geleijnse JM, Ding EL, Soedamah-Muthu SS: Effect of cheese consumption on blood lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev 2015;73:259-275.
25.
Hu FB, Stampfer MJ, Manson JE, Ascherio A, et al: Dietary saturated fats and their food sources in relation to the risk of coronary heart disease in women. Am J Clin Nutr 1999;70:1001-1008.
26.
Hjerpsted J, Leedo E, Tholstrup T: Cheese intake in large amounts lowers LDL-cholesterol concentrations compared with butter intake of equal fat content. Am J Clin Nutr 2011;94:1479-1484.
27.
de Oliveira Otto MC, Mozaffarian D, Kromhout D, Bertoni AG, et al: Dietary intake of saturated fat by food source and incident cardiovascular disease: the multi-ethnic study of Atherosclerosis. Am J Clin Nutr 2012;96:397-404.
28.
Lichtenstein AH: Nutrient supplements and cardiovascular disease: a heartbreaking story. J Lipid Res 2009;50(suppl):S429-S433.
29.
Törnwall ME, Virtamo J, Korhonen PA, Virtanen MJ, et al: Effect of alpha-tocopherol and beta-carotene supplementation on coronary heart disease during the 6-year post-trial follow-up in the ATBC study. Eur Heart J 2004;25:1171-1178.
30.
Miller ER 3rd, Juraschek S, Pastor-Barriuso R, Bazzano LA, et al: Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels. Am J Cardiol 2010;106:517-527.
31.
Mente A, de Koning L, Shannon HS, Anand SS: A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med 2009;169:659-669.
32.
GBD 2013 Risk Factors Collaborators, Forouzanfar MH, Alexander L, Anderson HR, et al: Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet 2015;386:2287-2323.
33.
Schwingshackl L, Hoffmann G: Dietary fatty acids in the secondary prevention of coronary heart disease: a systematic review, meta-analysis and meta-regression. BMJ Open 2014;4:e004487.
34.
Kwak SM, Myung SK, Lee YJ, Seo HG, et al: Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 2012;172:686-694.
35.
Schwingshackl L, Hoffmann G: Monounsaturated fatty acids and risk of cardiovascular disease: synopsis of the evidence available from systematic reviews and meta-analyses. Nutrients 2012;4:1989-2007.
36.
Schwingshackl L, Hoffmann G: Monounsaturated fatty acids, olive oil and health status: a systematic review and meta-analysis of cohort studies. Lipids Health Dis 2014;13:154.
37.
Pan A, Chen M, Chowdhury R, Wu JH, et al: α-Linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr 2012;96:1262-1273.
38.
Fretts AM, Mozaffarian D, Siscovick DS, Sitlani C, et al: Plasma phospholipid and dietary α-linolenic acid, mortality, CHD and stroke: the cardiovascular health study. Br J Nutr 2014;112:1206-1213.
39.
de Oliveira Otto MC, Wu JH, Baylin A, Vaidya D, et al: Circulating and dietary omega-3 and omega-6 polyunsaturated fatty acids and incidence of CVD in the multi-ethnic study of atherosclerosis. J Am Heart Assoc 2013;2:e000506.
40.
Sala-Vila A, Guasch-Ferré M, Hu FB, et al; PREDIMED Investigators: Dietary α-linolenic acid, marine ω-3 fatty acids, and mortality in a population with high fish consumption: findings from the prevención con dIeta Mediterránea (PREDIMED) study. J Am Heart Assoc 2016;5:pii:e002543.
41.
Mozaffarian D, Rimm EB: Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 2006;296:1885-1899.
42.
Bernstein AM, Ding EL, Willett WC, Rimm EB: A meta-analysis shows that docosahexaenoic acid from algal oil reduces serum triglycerides and increases HDL-cholesterol and LDL-cholesterol in persons without coronary heart disease. J Nutr 2012;142:99-104.
43.
Hedengran A, Szecsi PB, Dyerberg J, Harris WS, et al: n-3 PUFA esterified to glycerol or as ethyl esters reduce non-fasting plasma triacylglycerol in subjects with hypertriglyceridemia: a randomized trial. Lipids 2015;50:165-175.
44.
Iketani T, Takazawa K, Yamashina A: Effect of eicosapentaenoic acid on central systolic blood pressure. Prostaglandins Leukot Essent Fatty Acids 2013;88:191-195.
45.
Mozaffarian D, Geelen A, Brouwer IA, Geleijnse JM, et al: Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation 2005;112:1945-1952.
46.
Wu JH, Lemaitre RN, King IB, Song X, et al: Circulating omega-6 polyunsaturated fatty acids and total and cause-specific mortality: the cardiovascular health study. Circulation 2014;130:1245-1253.
47.
Brouwer IA, Wanders AJ, Katan MB: Trans fatty acids and cardiovascular health: research completed? Eur J Clin Nutr 2013;67:541-547.
48.
Jaudszus A, Kramer R, Pfeuffer M, Roth A, et al: Trans palmitoleic acid arises endogenously from dietary vaccenic acid. Am J Clin Nutr 2014;99:431-435.
49.
Bendsen NT, Christensen R, Bartels EM, Astrup A: Consumption of industrial and ruminant trans fatty acids and risk of coronary heart disease: a systematic review and meta-analysis of cohort studies. Eur J Clin Nutr 2011;65:773-783.
50.
Gayet-Boyer C, Tenenhaus-Aziza F, Prunet C, Marmonier C, et al: Is there a linear relationship between the dose of ruminant trans-fatty acids and cardiovascular risk markers in healthy subjects: results from a systematic review and meta-regression of randomised clinical trials. Br J Nutr 2014;112:1914-1922.
51.
Laake I, Pedersen JI, Selmer R, Kirkhus B, et al: A prospective study of intake of trans-fatty acids from ruminant fat, partially hydrogenated vegetable oils, and marine oils and mortality from CVD. Br J Nutr 2012;108:743-754.
52.
Gebauer SK, Destaillats F, Dionisi F, Krauss RM, et al: Vaccenic acid and trans fatty acid isomers from partially hydrogenated oil both adversely affect LDL cholesterol: a double-blind, randomized controlled trial. Am J Clin Nutr 2015;102:1339-1346.
53.
Brouwer IA, Wanders AJ, Katan MB: Effect of animal and industrial trans fatty acids on HDL and LDL cholesterol levels in humans - a quantitative review. PLoS One 2010;5:e9434.
54.
Mozaffarian D, de Oliveira Otto MC, Lemaitre RN, Fretts AM, et al: Trans-palmitoleic acid, other dairy fat biomarkers, and incident diabetes: the multi-ethnic study of atherosclerosis (MESA). Am J Clin Nutr 2013;97:854-861.
55.
Mozaffarian D, Cao H, King IB, Lemaitre RN, et al: Trans-palmitoleic acid, metabolic risk factors, and new-onset diabetes in U.S. adults: a cohort study. Ann Intern Med 2010;153:790-799.
56.
Kleber ME, Delgado GE, Lorkowski S, März W, et al: Trans-fatty acids and mortality in patients referred for coronary angiography: the Ludwigshafen risk and cardiovascular health study. Eur Heart J 2016;37:1072-1078.
57.
Mozaffarian D: Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review. Circulation 2016;133:187-225.
58.
Clarke R, Frost C, Collins R, Appleby P, et al: Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. BMJ 1997;314:112-117.
59.
Jebb SA, Lovegrove JA, Griffin BA, Frost GS, et al: Effect of changing the amount and type of fat and carbohydrate on insulin sensitivity and cardiovascular risk: the RISCK (Reading, Imperial, Surrey, Cambridge, and Kings) trial. Am J Clin Nutr 2010;92:748-758.
60.
Mensink RP, Zock PL, Kester AD, Katan MB: Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 2003;77:1146-1155.
61.
Vafeiadou K, Weech M, Altowaijri H, Todd S, et al: Replacement of saturated with unsaturated fats had no impact on vascular function but beneficial effects on lipid biomarkers, E-selectin, and blood pressure: results from the randomized, controlled dietary intervention and vascular function (DIVAS) study. Am J Clin Nutr 2015;102:40-48.
62.
Micha R, Mozaffarian D: Saturated fat and cardiometabolic risk factors, coronary heart disease, stroke, and diabetes: a fresh look at the evidence. Lipids 2010;45:893-905.
63.
Schwingshackl L, Strasser B, Hoffmann G: Effects of monounsaturated fatty acids on glycaemic control in patients with abnormal glucose metabolism: a systematic review and meta-analysis. Ann Nutr Metab 2011;58:290-296.
64.
Vlachopoulos C, Aznaouridis K, Stefanadis C: Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010;55:1318-1327.
65.
Livingstone KM, Givens DI, Cockcroft JR, Pickering JE, et al: Is fatty acid intake a predictor of arterial stiffness and blood pressure in men? Evidence from the Caerphilly prospective study. Nutr Metab Cardiovasc Dis 2013;23:1079-1085.
66.
Vessby B, Uusitupa M, Hermansen K, Riccardi G, et al: Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU study. Diabetologia 2001;44:312-319.
67.
Tierney AC, McMonagle J, Shaw DI, Gulseth HL, et al: Effects of dietary fat modification on insulin sensitivity and on other risk factors of the metabolic syndrome - LIPGENE: a European randomized dietary intervention study. Int J Obes (Lond) 2011;35:800-809.
68.
Morio B, Fardet A, Legrand P, Lecerf JM: Involvement of dietary saturated fats, from all sources or of dairy origin only, in insulin resistance and type 2 diabetes. Nutr Rev 2016;74:33-47.
69.
Sattar N, Gill JM: Type 2 diabetes as a disease of ectopic fat? BMC Med 2014;12:123.
70.
Rosqvist F, Iggman D, Kullberg J, Cedernaes J, et al: Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans. Diabetes 2014;63:2356-2368.
71.
Bjermo H, Iggman D, Kullberg J, Dahlman I, et al: Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am J Clin Nutr 2012;95:1003-1012.
72.
Wirfält E, Drake I, Wallström P: What do review papers conclude about food and dietary patterns? Food Nutr Res 2013;57:20523.
73.
von Ruesten A, Brantsæter AL, Haugen M, Meltzer HM, et al: Adherence of pregnant women to Nordic dietary guidelines in relation to postpartum weight retention: results from the Norwegian mother and child cohort study. BMC Public Health 2014;14:75.
74.
Sofi F, Abbate R, Gensini GF, Casini A: Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr 2010;92:1189-1196.
75.
Serra-Majem L, Roman B, Estruch R: Scientific evidence of interventions using the Mediterranean diet: a systematic review. Nutr Rev 2006;64(2 pt 2):S27-S47.
76.
Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, et al: Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-sodium collaborative research group. N Engl J Med 2001;344:3-10.
77.
Mithril C, Dragsted LO, Meyer C, Tetens I, et al: Dietary composition and nutrient content of the new Nordic diet. Public Health Nutr 2013;16:777-785.
78.
McCarron DA, Reusser ME: The power of food to improve multiple cardiovascular risk factors. Curr Atheroscler Rep 2000;2:482-486.
79.
Stradling C, Hamid M, Taheri S, Thomas GN: A review of dietary influences on cardiovascular health: part 2: dietary patterns. Cardiovasc Hematol Disord Drug Targets 2014;14:50-63.
80.
Brennan SF, Cantwell MM, Cardwell CR, Velentzis LS, et al: Dietary patterns and breast cancer risk: a systematic review and meta-analysis. Am J Clin Nutr 2010;91:1294-1302.
81.
Dominguez LJ, Bes-Rastrollo M, Basterra-Gortari FJ, Gea A, et al: Association of a dietary score with incident type 2 diabetes: the dietary-based diabetes-risk score (DDS). PLoS One 2015;10:e0141760.
82.
Maghsoudi Z, Ghiasvand R, Salehi-Abargouei A: Empirically derived dietary patterns and incident type 2 diabetes mellitus: a systematic review and meta-analysis on prospective observational studies. Public Health Nutr 2016;19:230-241.
83.
Cespedes EM, Hu FB, Tinker L, Rosner B, et al: Multiple healthful dietary patterns and type 2 diabetes in the Women's health initiative. Am J Epidemiol 2016;183:622-633.
84.
Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, et al: A clinical trial of the effects of dietary patterns on blood pressure. DASH collaborative research group. N Engl J Med 1997;336:1117-1124.
85.
Shirani F, Salehi-Abargouei A, Azadbakht L: Effects of dietary approaches to stop hypertension (DASH) diet on some risk for developing type 2 diabetes: a systematic review and meta-analysis on controlled clinical trials. Nutrition 2013;29:939-947.
86.
Sleiman D, Al-Badri MR, Azar ST: Effect of Mediterranean diet in diabetes control and cardiovascular risk modification: a systematic review. Front Public Health 2015;3:69.
87.
Esposito K, Maiorino MI, Bellastella G, Chiodini P, et al: A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses. BMJ Open 2015;5:e008222.
88.
Bonaccio M, Di Castelnuovo A, Costanzo S, Persichillo M, et al: Adherence to the traditional Mediterranean diet and mortality in subjects with diabetes. Prospective results from the MOLI-SANI study. Eur J Prev Cardiol 2016;23:400-407.
89.
Salas-Salvadó J, Bulló M, Babio N, Martínez-González MÁ, et al: Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial. Diabetes Care 2011;34:14-19.
90.
Martínez-González MA, Salas-Salvadó J, Estruch R, Corella D, et al: Benefits of the Mediterranean diet: insights from the PREDIMED study. Prog Cardiovasc Dis 2015;58:50-60.
91.
Uusitupa M, Hermansen K, Savolainen MJ, Schwab U, et al: Effects of an isocaloric healthy Nordic diet on insulin sensitivity, lipid profile and inflammation markers in metabolic syndrome - a randomized study (SYSDIET). J Intern Med 2013;274:52-66.
92.
Adamsson V, Reumark A, Fredriksson IB, Hammarström E, et al: Effects of a healthy Nordic diet on cardiovascular risk factors in hypercholesterolaemic subjects: a randomized controlled trial (NORDIET). J Intern Med 2011;269:150-159.
93.
Kanerva N, Rissanen H, Knekt P, Havulinna AS, et al: The healthy Nordic diet and incidence of type 2 diabetes - 10-year follow-up. Diabetes Res Clin Pract 2014;106:e34-e37.
94.
Kolehmainen M, Ulven SM, Paananen J, de Mello V, et al: Healthy Nordic diet downregulates the expression of genes involved in inflammation in subcutaneous adipose tissue in individuals with features of the metabolic syndrome. Am J Clin Nutr 2015;101:228-239.
95.
Lindström J, Peltonen M, Eriksson JG, Ilanne-Parikka P, et al: Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish diabetes prevention study (DPS). Diabetologia 2013;56:284-293.
96.
Roswall N, Sandin S, Löf M, Skeie G, et al: Adherence to the healthy Nordic food index and total and cause-specific mortality among Swedish women. Eur J Epidemiol 2015;30:509-517.
97.
Roswall N, Sandin S, Scragg R, Löf M, et al: No association between adherence to the healthy Nordic food index and cardiovascular disease amongst Swedish women: a cohort study. J Intern Med 2015;278:531-541.
98.
Lacoppidan SA, Kyrø C, Loft S, Helnæs A, et al: Adherence to a healthy Nordic food index is associated with a lower risk of type-2 diabetes - the Danish diet, cancer and health cohort study. Nutrients 2015;7:8633-8644.
99.
Esposito K, Chiodini P, Maiorino MI, Bellastella G, et al: Which diet for prevention of type 2 diabetes? A meta-analysis of prospective studies. Endocrine 2014;47:107-116.
100.
Kamau SM, Lu RR, Chen W, Liu XM, et al: Functional significance of bioactive peptides derived from milk proteins. Food Rev Int 2010;26:386-401.
101.
Lorenzen JK, Astrup A: Dairy calcium intake modifies responsiveness of fat metabolism and blood lipids to a high-fat diet. Br J Nutr 2011;105:1823-1831.
102.
Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ: Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet 2015;115:1447-1463.

Report of a Meeting of the Federation of European Nutrition Societies FENS, Berlin, October 23, 2015.

Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.